IL-6 polymorphism, anti-IL-6 therapy and animal models of multiple myeloma

Cytokine

Volumn 16, Issue 3, 2001, Pages 87-

  Jeffery, Rachel ^a,b   Mitchison, N Avrion ^a,b  

^a Windeyer Institute of Medical Sciences   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR;

ALLELISM; ANIMAL EXPERIMENT; ANIMAL MODEL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE MODEL; DRUG EFFICACY; GENETIC POLYMORPHISM; KNOCKOUT MOUSE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; NOTE; PLASMA CELL; PRIORITY JOURNAL;

ANIMALIA;

EID: 0035824186     PISSN: 10434666     EISSN: None     Source Type: Journal    
DOI: 10.1006/cyto.2001.0983     Document Type: Editorial

References (9)

1. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
2. Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects
3. Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery athersclerosis
4. A polymorphism in the promoter region of the gene for interleukin-6 is associated with susceptibility to type 1 diabetes mellitus
5. Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys
6. Therapeutic potential of humanized anti-interleukin-6 receptor antibody: Anti-tumor activity in xenograft model of multiple myeloma
7. Mouse plasmacytoma: An experimental model of human multiple myeloma
8. Interleukin-6 is essential for in vivo development of B lineage neoplasms
9. Adoptive immunotherapy with tumor-specific T lymphocytes generated from cytokine gene-modified tumor-primed lymph node cells